Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the Netherlands

de Boer, PTvan Werkhoven, CHvan Hoek, AJKnol, MJSanders, EAMWallinga, Jde Melker, HESteens, A2025-04-012025-04-0120243836064510.1186/s12916-024-03277-3https://rivm.openrepository.com/handle/10029/654973Higher-valency pneumococcal conjugate vaccines in older adults, taking into account indirect effects from childhood vaccination: a cost-effectiveness study for the NetherlandsArticleBMC Med 2024;22(1):692025-04-01